Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab rezetecan followed by CDK4/6i and ET in HR+/HER2-low/ultra-low advanced breast cancer
NCT07037199Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Started Aug 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07037199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037199.